On July 4, 2023, the recombinant anti§÷ human IL-4Ra and IL-5 double antibody∑≈ injection (RC1416 φδ★₹injection) independently developed by Nanjing Reg•∏&eneCore Biotech Co.,Ltd(herein•φ£←after referred to as RegeneCore)¶ε≥ completed the administration of the ✘↔₽₽first subject in CHINA-JAPAN FRIENDSHIP HOSPI™÷TAL, marking that the ™ →♦development of antibody drug§©¥≥s in RegeneCore has entered th£₽e clinical research stage. The puΩ∞δ₩rpose of this study was to evaluate the sa♥♦Ωfety and tolerability in Ch∑∞✘÷inese healthy subjects.

Rc1416 is the first bispecific antibody dru∏δg developed by RegeneCore based on nanλ<obody. By blocking IL-4, IL-5 and IL-13  ≈signaling pathways, it can be used for the t&♥reatment of diseases r∏αφelated to excessive activ​→™ation of Th2 immune c∑∞÷"ell pathways.

REGENECORE is gradually practicing clΩ& inical demand and market-oriente₹'±δd technological innovation, and co♠♥ntinues to move firmly on the road of ≠✘φ"Make a better lif≤€§e with innovative medicines".<×

Figure 1: Schematic diagr✔γ↑®am of molecular mechan¶γisms related to Th2 inflammation[©≤1]

Reference:

[1]Gandhi NA, Bennett B•♣↕♣L, Graham NM, Pirozzi G, Stahl N, Yancopoulos✔δ¥ GD. Targeting key proximal drivers of type 2 in♣α∑λflammation in disease. Na€≠t Rev Drug Discov. 2016 Jan;15γ®(1):35-50. doi: 10.1038/nrd4624. Epub 2015 Oc±π♦t 16. PMID: 26471366.Reference: ≠&γ